Product for Licensing

• Product for Licensing

  For Licensing: Multi-Target Oral Brain-Penetrable Small Molecule for ASD, High Selectivity & High Binding Affinity

  2026年7月8日
• Product for Licensing

  Asset for Licensing: 11β-HSD1 Inhibitor, Oral QD candidate for MASH & IPF indications

  2026年7月8日
• Product for Licensing

  Probiotic Vaccine Platform Seeking Collaboration Partners

  2026年7月8日
• Product for Licensing

  Asset for Licensing: Dual-Target siRNA Therapeutics

  2026年7月7日
• Product for Licensing

  Are you looking for siRNA assets for obesity, diabetes, cardiovascular, MASH, HBV and other diseases?

  2026年6月11日
• Product for Licensing

  Are you looking for oral small-molecule inhibitors of CYP11A1 for metastatic castration-resistant prostate cancer (mCRPC)?

  2026年6月11日
• Product for Licensing

  A Best-in-class potential Lp(a) siRNA for licensing | DrugTimes BD Project

  2026年5月14日
• PCC

  A Best-in-Class Oral Small-Molecule GLP-1 Receptor Agonist with Superior Weight Loss and Appetite Suppression Efficacy | DrugTimes BD Opportunity

  2025年8月19日
• Product for Licensing

  【SELL】A Highly Potent, Selective, Tissue-Enriched Oral Pan-KRAS (ON & OFF) Inhibitor for licensing

  2025年8月12日
• Small Molecule

  A Potentially Best-in-Class (BIC) Pan-RAS (ON) Inhibitor with Superior PK Profile and Significant Pharmacological Efficacy

  2025年8月4日